Advertising disclosure: we may earn a commission when you buy through links on this site. How we make money

HomeTrials › NCT05018286

Other · Phase 3 · Active, not recruiting

Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.

NCT05018286 · Sponsor: VectivBio AG

What this trial means for you

This study is active, not recruiting — it is not currently taking new participants, but its results may matter for treatments you're considering. It's studying Apraglutide for short bowel syndrome.

Who can joinAll sexes, 18 Years and older
Healthy volunteersNo — diagnosis required
What you'd takeApraglutide
Study length~6.3 years overall
Planned participants158
TypeInterventional (you receive treatment)

What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study — ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.

The study, in the sponsor's words

The primary objective of the trial is to assess long-term safety and tolerability of apraglutide in subjects with SBS-IF.

Can you join? The exact criteria

Below is the verbatim eligibility text from the registry — bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.

Full eligibility criteria (for you and your doctor)

Inclusion Criteria: 1. Males and females with a diagnosis of SBS-IF secondary to surgical resection of the small intestine, with Colon-in-Continuity (CIC) or stoma, who were trial subjects of parent trials TA799-007 or TA799-013 2. Able to give informed consent and agree to follow the details of participation as outlined in the protocol. Exclusion Criteria: 1. Subject not capable of understanding or not willing to adhere to the trial visit schedules and other protocol requirements. 2. Any other reason judged not eligible by the Investigator. 3. Pregnancy or lactation

Study sites by state

California

  • Ronald Reagan UCLA Medical Center — Los Angeles

Florida

  • Gastroenterology Group of Naples — Naples

Illinois

  • Northwestern University - Chicago — Chicago

Michigan

  • Henry Ford Health System — Detroit

Minnesota

  • Mayo Clinic - Rochester — Rochester

Nebraska

  • University of Nebraska Medical Center — Omaha

New York

  • Mount Sinai Medical Center — New York

North Carolina

  • Duke University Medical Center — Durham

Ohio

  • Cincinnati Children's Hospital Medical Center — Cincinnati
  • Cleveland Clinic Foundation — Cleveland

Pennsylvania

  • Hospital of the University of Pennsylvania — Philadelphia

Tennessee

  • Vanderbilt University Medical Center — Nashville

Washington

  • University of Washington Medical Center — Seattle

View the official record on ClinicalTrials.gov →

Verify before you act. Medical disclaimer: content on this site is for informational purposes only and is not medical advice. GLP-1 medications are prescription drugs; always consult a licensed healthcare provider about eligibility, risks, and benefits. Trial details and enrollment status change frequently — always verify on the official registry and talk to your own clinician before contacting a study site. This page was generated from registry data and is not affiliated with the study sponsor.

Follow this trial

Get an email when our monthly digest covers enrollment changes and results for trials like this one.

Newsletter signup launches soon. (Site owner: set PUBLIC_BUTTONDOWN_USERNAME in .env to activate this form.)

Keep researching on StudyBackedHealth